Listed

Sanofi: Form 20-F for the period ended Dec 31, 2023

Filed with the SEC on Feb 23, 2024 and accepted by EDGAR at Feb 23, 2024, 11:15 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Cost of revenue12 months2023-01-01 to 2023-12-31EUR 14.24bnifrs-full:CostOfSales
Gross profit12 months2023-01-01 to 2023-12-31EUR 32.21bnifrs-full:GrossProfit
Operating income12 months2023-01-01 to 2023-12-31EUR 7.88bnifrs-full:ProfitLossFromOperatingActivities
Income tax12 months2023-01-01 to 2023-12-31EUR 1.60bnifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2023-01-01 to 2023-12-31EUR 5.40bnifrs-full:ProfitLossAttributableToOwnersOfParent
Operating cash flow12 months2023-01-01 to 2023-12-31EUR 10.26bnifrs-full:CashFlowsFromUsedInOperatingActivities
Cash and equivalentsAt period end2023-12-31EUR 8.71bnifrs-full:CashAndCashEquivalents
Total assetsAt period end2023-12-31EUR 126.46bnifrs-full:Assets
Shareholders' equityAt period end2023-12-31EUR 74.04bnifrs-full:EquityAttributableToOwnersOfParent
Shares outstandingAt period end2023-12-311,264,799,969 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001121404-24-000009. Last ingested by Listed: Nov 5, 2026, 12:26 ET. Listed shows no prices and gives no investment advice.